查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1790258

美国照护现场药物滥用检测市场规模、份额及趋势分析报告：按产品、样本类型、技术、最终用途和细分市场进行预测，2025 年至 2033 年

U.S. Point of Care Drug of Abuse Testing Market Size, Share & Trends Analysis Report By Product, By Sample Type, By Technology, By End-use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国照护现场药物滥用检测市场概况

据估计，2024 年美国照护现场药物滥用检测市场规模将达到 3.7055 亿美元，预计 2025 年至 2033 年的复合年增长率将达到 9.3%。这一市场的成长动力源于在多种环境下进行快速现场药物检测的需求日益增长。照护现场诊断 DOA 检测（包括尿液、唾液，有时还有血液检测）广泛应用于职场、急诊室、警察局、復健中心、学校等。这些检测可立即提供结果，帮助医疗专业人员和机构更快地做出与患者照护、依从性和风险缓解相关的决策。它们的便携性和易用性进一步推动了实验室以外专业人士对其的采用，从而促进了市场渗透。

市场驱动因素之一是美国药物滥用氾滥，尤其是鸦片类药物、大麻、古柯碱和安非他命。根据美国国家药物滥用统计中心的数据，到2023年，将有超过2,000万12岁及以上的美国人患有药物滥用障碍。这一日益增长的趋势推动了对高效药物筛检工具的需求，尤其是在紧急和职业健康环境中。此外，来自联邦机构（例如药物滥用和精神健康服务管理局 (SAMHSA)）和州级阿片类药物应对计画的资金增加，也推动了快速检测工具的普及。

交通运输、建筑和医疗保健等安全关键行业强制要求进行入职前、随机和事故后药物检测，这极大地促进了市场成长。美国运输部(DOT) 和其他监管机构已实施严格要求，强制雇主实施 DOA筛检通讯协定。在这些环境中，POC 检测尤其重要，因为它能够快速识别中毒和近期吸毒情况，有助于减轻法律责任并确保工人安全。

目录

第一章调查方法与范围

第二章执行摘要

第 3 章美国照护现场药物滥用检测市场变数、趋势与范围

  • 市场介绍/电网展望
  • 市场规模和成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 美国照护现场药物滥用检测市场分析工具
    • 波特分析
    • PESTEL分析

第四章。美国照护现场药物滥用检测市场（按产品、估计和趋势分析）

  • 美国照护现场药物滥用检测市场：产品差异分析
  • 按产品划分，2024 年和 2033 年
  • 免疫检测条和测试盒
  • 口腔液体检测套组
  • 呼吸分析仪
  • 尿液收集杯
  • 数位/可携式分析仪

第五章美国照护现场药物滥用检测市场（按样本类型、估计和趋势分析）

  • 美国照护现场药物滥用检测市场：样本类型变异分析
  • 样本显示，2024 年和 2033 年
  • 尿
  • 唾液（口腔液体）
  • 呼吸
  • 血
  • 汗水/头髮

第六章。美国照护现场药物滥用检测市场（按技术、估计和趋势分析）

  • 美国照护现场药物滥用检测市场：技术变革分析
  • 按技术划分，2024 年和 2033 年
  • 横向流动化验（LFA）
  • 层析法免疫检测
  • 酵素免疫分析法（ELISA）
  • 质谱法（可携式或混合式 POC 装置）

第七章。美国照护现场药物滥用检测市场最终用途、预测与趋势分析

  • 美国照护现场药物滥用检测市场：最终用途变异分析
  • 依最终用途，2024 年和 2033 年
  • 医院和急诊部
  • 职场和职业健康中心
  • 居家医疗和远端用户
  • 其他的

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 公司热图分析
  • 公司简介
  • 公司简介/上市公司
    • Abbott
    • Quest Diagnostics Inc
    • Thermo Fisher Scientific
    • OraSure Technologies
    • Siemens Healthineers
    • F. Hoffmann-La Roche Ltd.
    • Dragerwerk AG & Co. KGaA
    • Premier BIoTech
    • American Screening Corporation, Inc.
    • Aegis Sciences Corporation
    • MP Biomedicals
    • Innovacon（Alere, Abbott）
Product Code: GVR-4-68040-659-9

U.S. Point Of Care DOA Testing Market Summary

The U.S. point of care drug of abuse (DOA) testing market size was estimated at USD 370.55 million in 2024 and is projected to grow at a CAGR of 9.3% from 2025 to 2033. The market is driven by an increasing need for rapid and on-site drug testing across multiple settings. Point-of-care DOA tests, which include urine, saliva, and occasionally blood-based panels, are widely used in workplaces, emergency departments, law enforcement, rehabilitation centers, and schools. These tests offer immediate results, helping healthcare professionals and institutions make faster decisions related to patient care, compliance, and risk mitigation. Their portability and ease of use are further increasing their adoption among non-laboratory professionals, contributing to market penetration.

One of the primary market drivers is the escalating incidence of drug abuse in the U.S., particularly related to opioids, cannabis, cocaine, and amphetamines. According to the National Center for Drug Abuse Statistics, over 20 million Americans aged 12 and older had a substance use disorder in 2023. This rising trend has heightened the demand for efficient drug screening tools, particularly in emergency and occupational health settings. Additionally, increased funding from federal agencies such as SAMHSA (Substance Abuse and Mental Health Services Administration) and state-level opioid response programs has bolstered the adoption of rapid testing tools.

Mandates for pre-employment, random, and post-incident drug testing in safety-sensitive industries such as transportation, construction, and healthcare are significantly contributing to market growth. The U.S. Department of Transportation (DOT) and other regulatory bodies have stringent requirements that compel employers to implement DOA screening protocols. POC testing is especially valued in these settings for its ability to quickly identify intoxication or recent drug use, helping mitigate legal liability and ensure workforce safety.

U.S. Point of Care Drug of Abuse Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. point of care drug of abuse (DOA) testing market report based on product, sample type, technology, and end-use:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunoassay Test Strips and Cassettes
  • Oral Fluid Testing Kits
  • Breath Analyzers
  • Urine Collection Cups
  • Digital/Portable Analyzers
  • Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Urine
  • Saliva (Oral Fluid)
  • Breath
  • Blood
  • Sweat/Hair
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Lateral Flow Assay (LFA)
  • Chromatographic Immunoassays
  • Enzyme-linked Immunosorbent Assay (ELISA)
  • Mass Spectrometry (Portable or Hybrid POC Units)
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Emergency Departments
  • Workplace & Occupational Health Center
  • Home Care & Remote Users
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Point of Care Drug of Abuse (DOA) Testing Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising substance abuse rates and opioid crisis
      • 3.3.1.2. Increased adoption in workplace and law enforcement
      • 3.3.1.3. Shift toward non-invasive and rapid testing methods
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Stringent Regulations
    • 3.3.3. Market Opportunities Analysis
    • 3.3.4. Market Challenges Analysis
      • 3.3.4.1. Product Recalls
  • 3.4. U.S. Point of Care Drug of Abuse (DOA) Testing Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Product Movement Analysis
  • 4.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by Product (USD Million), 2024 & 2033
  • 4.3. Immunoassay Test Strips and Cassettes
    • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Oral Fluid Testing Kits
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Breath Analyzers
    • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Urine Collection Cups
    • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Digital/Portable Analyzers
    • 4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Estimates & Trend Analysis

  • 5.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Sample Movement Analysis
  • 5.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by Sample (USD Million), 2024 & 2033
  • 5.3. Urine
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Saliva (Oral Fluid)
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Breath
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Blood
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Sweat/Hair
    • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Technology Estimates & Trend Analysis

  • 6.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Technology Movement Analysis
  • 6.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by Technology (USD Million), 2024 & 2033
  • 6.3. Lateral Flow Assay (LFA)
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Chromatographic Immunoassays
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Mass Spectrometry (portable or hybrid POC units)
    • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Point of Care Drug of Abuse (DOA) Testing Market: End Use Estimates & Trend Analysis

  • 7.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market: End-use Movement Analysis
  • 7.2. U.S. Point of Care Drug of Abuse (DOA) Testing Market Estimates and Forecasts, by End-use (USD Million), 2024 & 2033
  • 7.3. Hospitals & Emergency Departments
    • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Workplace & Occupational Health Center
    • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Home Care & Remote Users
    • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
  • 8.5. Company Profiles/Listing
    • 8.5.1. Abbott
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Quest Diagnostics Inc
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Thermo Fisher Scientific
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. OraSure Technologies
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Siemens Healthineers
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. F. Hoffmann-La Roche Ltd.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Dragerwerk AG & Co. KGaA
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Premier Biotech
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. American Screening Corporation, Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Aegis Sciences Corporation
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. MP Biomedicals
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Innovacon (Alere, Abbott)
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 3 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Sample Type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 5 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 U.S. point of care drug of abuse (DOA) testing market- Key market driver analysis
  • Fig. 7 U.S. point of care drug of abuse (DOA) testing market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 U.S. point of care drug of abuse (DOA) testing market - Porter's analysis
  • Fig. 10 U.S. point of care drug of abuse (DOA) testing market - PESTEL analysis
  • Fig. 11 U.S. point of care drug of abuse (DOA) testing market product outlook key takeaways
  • Fig. 12 U.S. point of care drug of abuse (DOA) testing market: Product movement analysis
  • Fig. 13 Immunoassay Test Strips and Cassettes
  • Fig. 14 Oral Fluid Testing Kits market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Breath Analyzers market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Urine Collection Cups market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Digital/Portable Analyzers market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 U.S. point of care drug of abuse (DOA) testing market sample type outlook key takeaways
  • Fig. 19 U.S. point of care drug of abuse (DOA) testing market: sample type movement analysis
  • Fig. 20 Urine market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Saliva (Oral Fluid) market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Breath market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Blood market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Sweat/Hair market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. point of care drug of abuse (DOA) testing market technology outlook key takeaways
  • Fig. 26 U.S. point of care drug of abuse (DOA) testing market: technology movement analysis
  • Fig. 27 Lateral Flow Assay (LFA) market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Chromatographic Immunoassays market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Enzyme-Linked Immunosorbent Assay (ELISA) market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Mass Spectrometry (portable or hybrid POC units) market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. point of care drug of abuse (DOA) testing market end use outlook key takeaways
  • Fig. 32 U.S. point of care drug of abuse (DOA) testing market: sample type movement analysis
  • Fig. 33 Urine market estimates, 2021 - 2033 (USD Million)